Followers | 3 |
Posts | 1503 |
Boards Moderated | 0 |
Alias Born | 02/07/2016 |

Saturday, May 17, 2025 1:27:55 AM
Not that I need to explain my activities to you, but I played three sets of tennis and 9 holes of golf today. I was off this week and had time between various activities to write about Halozyme specially with such big news.
It's quite puzzling that a shareholder like you would spend so much time fighting another halo long over something clearly mutually beneficial to all shareholders Ask yourself what would happen to the share price if on Monday if there was an SEC filing by the CFO and a few of the directors showing they bought shares in the open market. If you wanna know the answer, look at what happened to United Health today with their insiders buying shares.
If you do not have anything to say with regards to the substance of this discussion, I recommend you do not reply.
Recent HALO News
- Halozyme Therapeutics Added to Russell 1000® Index • PR Newswire (US) • 06/30/2025 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/24/2025 09:40:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/20/2025 08:25:04 PM
- Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) • PR Newswire (US) • 06/20/2025 05:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2025 09:33:05 PM
- Halozyme to Participate at Upcoming Investor Conferences • PR Newswire (US) • 05/28/2025 08:05:00 PM
- Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications • PR Newswire (US) • 05/28/2025 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2025 08:08:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2025 08:06:31 PM
- HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS • PR Newswire (US) • 05/06/2025 08:01:00 PM
- Halozyme to Participate in the BofA Securities 2025 Healthcare Conference • PR Newswire (US) • 05/05/2025 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2025 08:11:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2025 08:08:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/02/2025 08:07:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2025 08:06:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2025 08:04:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2025 08:02:32 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/28/2025 09:18:36 PM
- Halozyme to Report First Quarter 2025 Financial and Operating Results • PR Newswire (US) • 04/28/2025 12:30:00 PM
- Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) • PR Newswire (US) • 04/28/2025 11:30:00 AM
- Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation • PR Newswire (US) • 04/24/2025 12:30:00 PM
- Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy • PR Newswire (US) • 04/10/2025 10:15:00 PM
- European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility • PR Newswire (US) • 04/09/2025 12:45:00 PM
- European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer • PR Newswire (US) • 04/07/2025 01:29:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2025 10:32:16 PM
FEATURED Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment • Jul 8, 2025 8:30 AM
Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America • AVAI • Jul 8, 2025 8:00 AM
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs • CLDI • Jul 7, 2025 9:00 AM
VAYK Discloses More Insider Buying Approaching 15 Million • VAYK • Jul 2, 2025 10:37 AM
Patented, Groundbreaking Blockchain for Public Companies 'BlackStar Digital Trading PlatformTM' can Facilitate U.S. Registered Securities to Trade on Blockchain Without Tokens. • BEGI • Jul 1, 2025 12:54 PM
UC Asset (UCASU) Public Offering's Acquisition Target Reported Better Results • UCASU • Jul 1, 2025 9:15 AM